LONDON (Reuters) - Bristol-Myers Squibb's leukaemia drug Sprycel and rival Novartis product Tasigna are not worth using on the state health service, the country's healthcare cost watchdog said.
Source: http://uk.reuters.com/article/2011/05/05/uk-britain-leukaemia-drugs-idUKTRE74482320110505?feedType=RSS&feedName=domesticNews
pets food restaurants science
No comments:
Post a Comment